期刊
TRENDS IN PHARMACOLOGICAL SCIENCES
卷 30, 期 11, 页码 581-591出版社
ELSEVIER SCIENCE LONDON
DOI: 10.1016/j.tips.2009.08.002
关键词
-
资金
- American Australian Association Merck Company Foundation Fellowship
- National Health and Medical Research Council CJ Martin Fellowship [ID 465423]
- NIH [DA015642, DA017670, DA024044, DE017782]
- National Institute on Drug Abuse
- National Institute on Alcohol Abuse and Alcoholism
Glial activation participates in the mediation of pain including neuropathic pain, due to release of neuroexcitatory, proinflammatory products. Glial activation is now known to occur in response to opioids as well. Opioid-induced glial activation opposes opioid analgesia and enhances opioid tolerance, dependence, reward and respiratory depression. Such effects can occur, not via classical opioid receptors, but rather via non-stereoselective activation of toll-like receptor 4 (TLR4), a recently recognized key glial receptor participating in neuropathic pain as well. This discovery identifies a means for separating the beneficial actions of opioids (opioid receptor mediated) from the unwanted side-effects (TLR4/glial mediated) by pharmacologically targeting TLR4. Such a drug should be a stand-alone therapeutic for treating neuropathic pain as well. Excitingly, with newly-established clinical trials of two glial modulators for treating neuropathic pain and improving the utility of opioids, translation from rats-to-humans now begins with the promise of improved clinical pain control.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据